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Schizophrenia, in general, is characterized by severe and disabling mental alterations, characterized by 
the impairment of one’s mental, behavioral and social activities, developing certain clinical symptoms, 
relevant to the diagnosis. The drugs used for the reversion of the symptoms cause several adverse effects 
that affect the patient’s health and well-being, such as motor, endocrine and cardiovascular damages. 
For a long time, little was known about the origin and the treatment of schizophrenia, which has become 
a curiosity for science, originating countless researches and theories that are background for several 
treatments. It is known that alterations in dopaminergic pathways are related to the development of 
the symptoms of the disease, and evaluating these symptoms, the diagnosis is made and the treatment 
is initiated. The insertion of new drugs with different characteristics and mechanisms tends to be an 
advance in the treatment of schizophrenia, as well as reducing the occurence of adverse effects or not 
worsening already existing cases. Aripiprazole is an innovative atypical antipsychotic employed in the 
pharmacotherapy of schizophrenia, which tends to attenuate the symptoms, inducing few adverse effects 
compared to other drugs that are already used, and promotes better quality of life to patients. 
Keywords: Schizophrenia. Pharmacotherapy. Antipsychotics. Aripiprazole. Metabolic Syndrome. 
INTRODUCTION
Schizophrenia is a severe and disabling mental 
disorder that commonly appears in the transition of 
adolescence to the adult phase, characterized by the 
impairment of cerebral, behavioral and social functions 
(Falkai et al., 2006). It is one of the most intriguing 
and studied psychic conditions, due to its clinical 
and psychopathological characteristics, in which 
individuals are affected in the height of their productive 
potentital, being its progression chronic and disabling 
(Nicolino et al., 2011).
The different symptoms caused by schizophrenia 
seem to result from the malfunctioning of different 
neuronal networks. It is known that alterations in 
dopaminergic pathways are the main ones involved in the 
development of the symptoms of this disease (Rang et al., 
2016). Alterations in the mesolimbic pathway seem 
to be more related to the development of the positive 
symptoms, while alterations in the mesocortical pathways 
are more related to the origin of the negative symptoms 
of the disease. Such positive symptoms usually appear 
in the beginning of the disease, developing abnormal 
cerebral functions, including delirium, hallucinations, 
disorganized speech and abnormal psychomotor behavior, 
such as catatonia. As for the negative symptoms, they 
are characterized by the reduction of total loss of normal 
behavioral functions, causing impairments such as 
alogy (lack of coherence in speech and organization of 
ideas), affective flattening, avolition (low goal-directed 
actions) and inconcise speech, being that these symptoms 
accompany the patient throughout their entire lives 
(Golan et al., 2014).
Considering that schizophrenia is a disease of 
idiopathic cause, it was not until fairly recently that a 
fair number of studies that correlated its origin with 
possible treatments were made, and the resources to treat 
the patients are scarce and not well known. Thus, the 
insertion of antipsychotic medication was a primordial 
fator of change in this scenario, as later, individuals were 
instructed towards to the correct treatment, associating 
them with symptoms that were pertinent to the disease. 
The antipsychotics are divided into two therapeutic classes 
that differ from one another basically by therapeutic 
potency and relative affinity to receptors, so that such 
affinities are directly related to the clinical efficacy, 
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therapeutic response, as well as to the development of 
adverse effects (Silva, 2006). 
T h i s  w o r k  a i m s  t o  a d d r e s s  p h y s i o -  a n d 
psychopathological aspects of schizophrenia in order to 
correlate the already known pharmacological treatments 
with new drugs inserted in therapeutic, evidencing 
aripiprazole and its pharmacological activities in 
schizophrenia, which seem to significantly improve 
quality of life and the maintenace of the patient’s health. 
MATERIAL AND METHODS
The present study was written in the form a review 
article, using data from literature. For this, books regarding 
this subject were used, such as: Katzung, Goodman, 
Rang & Dale, Golan, Penildon and Silva, etc. Research 
in databases was made, such as NCBI, Pubmed, Scielo, 
LILAC, among others, through key-words where a relation 
between schizophrenia, antipsychotics, dyslipidemia and 
antipsychotics, atypical antipsychotics, aripiprazole and 
schizophrenia, was made, among other ones pertinent to the 
subject. The articles were selected based on the relevance 
towards the subject in question, so that a justification based 
in literature would be described, prioritizing studies of more 
recent publication date, from 2000 to 2018. 
Schizophrenia
Schizophrenia is a severe and disabling mental 
disorder, characterized by the occurence of one or more 
psychotic episodes that affect the sense of reality. It 
usually affects young people and persist throughout life, 
and may develop serious complications in the patient 
(Wirshing, 2004). Clinical manifestations are classified 
in two categories, according to symptomatology: positive 
and negative symptoms (Brunton, Chabner, Knowmann, 
2012).
Positive symptoms are related to the development of 
abnormal functions and usually appear in the beginning of 
the disease, in the diagnostic phase. Such symptoms include 
delirium (distortion in the interpretation and perception), 
hallucination (abnormal auditive perceptions), catatonia 
(involuntary blunt movements, static position, muscular 
stiffness, bizarre posture, sometimes voluntary, stupor), 
among others that affect cerebral function. The negative 
symptoms are characterized by the loss or reduction of 
normal behavioral activities, leading to the development 
of symptoms such as affective flattening, anhedonia, alogy, 
avolition, social retraction, among others that are evident 
in the chronic phase of the disease, accompanying the 
individuals throughout life (Falkai et al., 2006).
Although schizophrenia does not present a definite 
origin, it is believed that it is a disease of multifactorial 
cause, that is, there are several hypothesis studied until 
today that aim to explain the variables of the causes and 
contribute to the adequate treatment (Helbert, 2014).
Genetic theory
The genetic theory presents a combination of 
genetic and environmental factors, which indicated that 
the individual may present a genetic polymorphism that 
predisposes them to schizophrenia, however exposure to 
environmental factors is necessary for the development 
of the disease. There is strong but incomplete hereditary 
evidence, that indicate that in first degree relatives, the risk 
of developing the disease is around 10%, but in identical 
twins, if one presentes schizophrenia, the probability that 
the other one has the characteristic genes is 50%, which 
indicates that, for the development of schizophrenia in 
this one, exposure to environmental factors is necessary 
(Rang et al., 2016).
Neurodevelopmental theory
This hypothesis supposes that the development 
of schizophrenia is related to possible neuroanatomical 
alterations that occur during the brain embryonic phase, 
so that these alterations do not seem to show until 
adolescence and the beginning of the adult phase. In 
addition, environmental and epigenetic factors (inherited 
genetic modifications) seem to have a direct relation with 
neurodevelopment, so that the earlier the contact with 
external factors happen, such as maternal viral exposure 
or obstetricial conditions that may put fetal formation at 
risk, such as lack of necessary supplements for neuronal 
formation, such as glucose, iodine and iron, reduction 
in oxygen supply, among others, might lead to the 
poor development of the central nervous system (CNS) 
(Londero et al., 2015).
Dopaminergic theory
The dopaminergic theory is the best-accepted theory 
nowadays and the most used in the clinical diagnosis of 
schizophrenia. This theory takes into account that the 
disease is caused by an overproduction or dysregulated 
production of dopamine (DA), or by an increased 
sensibility of the dopaminergic receptores in different 
brain regions (Golan, et al., 2014).
It is believed that the dysregulation in dopamine 
levels in schizophrenic patients occurs in specific 
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brain regions, and these regions are responsible for the 
development of the several characteristic symptoms. 
The mesolimbic pathway seems to be related to the 
development and maintenance of emotions and memory, 
and the result of a hyperactivity in this region is associated 
with the appearance of the positive symptoms. As for a 
hypoactivity in the mesocortical pathway, it affects frontal 
brain regions that are responsible for the development of 
normal brain function, such as attention, oriented behavior 
and planning; so that such behaviors may be related to 
the development of the negative symptoms (Falkai et al., 
2006).
Some studies indicated that drugs of abuse that 
increase DA levels in the mesolimbic pathway such as 
cocaine, might be related to the development of the positive 
symptoms of the disease, as well as to the aggressive 
behaviors. Cocaine acts by blocking the dopamine 
transporter (DAT), inhibiting the reuptake of the DA 
from the synaptic cleft (Brunton, Chabner, Knowmann, 
2012); and the result of the excessive stimulation of these 
dopaminergic receptors denotes similar alterations to the 
positive symptoms of schizophrenia, including euphoria, 
emotional instability, hallucination, irritability, among 
others (Costa, Mac, 2012). 
Besides dopamine, other non-dopaminergic 
neurotransmitters, such as serotonin and glutamate, seem 
to be involved in the pathophysiology of schizophrenia. 
Some studies suggest that drugs such lysergic acid 
diethylamide (LSD) can develop a series of cognition 
changes, paranoia and perception, which ressembles 
some schizophrenic symptoms, and a possible explanation 
for this is that these drugs have a structure similar to 
serotonin and high affinity for serotonin receptors, and 
that hyperarousal or increased sensitivity of receptors 
to the drug, promotes the development of symptoms 
(Howes, Mc Cutcheon, Stone, 2015).There are some 
hypothesis that indicate that serotonin receptor (5HT2A) 
antagonists and the blockade of DA receptors constitute an 
important mechanism for the pharmacological treatment 
of schizophrenia, so that this is the mechanism of action 
of second generation antipsychotics (Helbert, 2014). 
Taking into account that glutamate is the most abundant 
neurotransmitter in the CNS, some authors suggest that the 
occurence of the negative symptoms may be related to the 
antagonism of glutamate receptors (NMDA), which would 
cause an increase in the levels of synpatic glutamate and 
consequent stimulation of non-NMDA receptores, being 
these receptores responsible for the induction of psychosis 
(Bessan, Pilowsky, 2003).
In order to minimize these symptoms, fundamental 
drugs for the treatment of schizophrenia were developed, 
as well as to improve quality of life, causing reduction in 
psychotic crisis and inserting patients in the society, in 
order to improve their acceptance (Azevedo et al., 2006).
Pharmacological treatment 
The dopaminergic hypothesis was essential for 
the development of the first therapeutic classes of 
antipsychotic agents, called the typical antipsychotics or 
first-generation antipsychotics. The greatest examples 
of this class are chlorpromazine, which belongs to the 
phenothiazine class, and haloperidol, which belongs to 
the butyrophenone class; the first-generation antipsychotic 
class (FGA) differ among them in potency, but share the 
same mechanism of action, the significant blockade of 
D2 DA receptors. These drugs are associated with few 
effective results in the control of the negative symptoms 
of schizophrenia, indicating that this low efficacy might 
be related to the hypothesis that the negative symptoms 
are correlated with the hypoactivity of neurons located 
in the mesocortical region, and that these drugs are not 
capable of correcting this hypoactivity (Brunton, Chabner, 
Knowmann, 2012).
Studies show that high potency FGA agents, such 
as haloperidol, are associated to the occurence of several 
extrapyramidal effects (EPE), which are characterized 
by disturbances of movement such as tardive dyskinesia; 
besides, they are associated to the occurence of sedation, 
postural hypotension, anticholinergic and adrenergic 
effects (Irving, Bergman, Adams, 2013). As for the low 
potency FGA such as chlorpromazine, they are associated 
to low induction of EPE, but higher risk of sedation, 
postural hypotension and tachycardia, as well as high risk 
of anticholinergic and antiadrenergic effects. In a study 
regarding the efficacy of chlorpromazine as a low potency 
FGA agent, showed a discrete improvement of therapy 
with chlorpromazine compared to placebo, however 
showing more adverse effects related to the treatment 
(Adams et al., 2007).
Among the EPE caused by FGA, the Neuroleptic 
Malignant Syndrome (NMS) is the most severe and 
concerning, because about 10% of total cases lead to 
death. The NMS is characterized by catatonia (motor 
dysfunction), stupor (profound unconsciousness and 
insensibility to the environment), fever and autonomic 
instability. After some time, when receptors are 
hypersensitive to DA, most patients in treatment with FGA 
show an improvement of the catatonic effects, also called 
parkinsonian effects. However, after chronic use of these 
drugs for months or years, around 20% of individuals may 
develop tardive dyskinesia, a disturbance of motor activity 
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characterized by involuntary and repetitive facial muscles, 
arms and body. The exact mechanism responsible for this 
situation is still unknown, but it is believed that it may 
be related to adaption of receptors, resulting in excessive 
dopaminergic activity (Golan et al., 2014). However, all 
antipsychotics may cause significant adverse effects of 
variable proportions, being chlorpromazine, thyoridazine, 
haloperidol, among others belonging to the FGA class, the 
ones showing greater EPE (Falkai et al., 2006).
The large range of adverse effects caused by 
conventional antipsychotics led to the development of 
a new therapeutic class for psychosis, called second-
generation antipsychotic (SGA) drugs, or atypical 
antipsychotics. These drugs promote better results in 
the treatment of schizophrenia, because they tend to 
produce significantly less adverse effects compared to 
typical antipsychotics, showing more patient adhesion 
to treatment, contributing to the improvement of quality 
of life (Azevedo et al., 2006). In addition, they act by 
minimizing the positive and negative symptoms, due to 
its different mechanism of action, which make these drugs 
more effective in the treatment, as well as by lowering 
suicidal and depressive tendencies, and by the reduction 
of aggressive and impulsive behavior (Rocha et al., 2010).
The main examples of this group of drugs 
are: risperidone, clozapine, olanzapine, quetiapine, 
ziprasidone and aripiprazole. These drugs, in addition to 
lower induction of adverse effects, seem to be effective 
in the negative symptoms (Morais, Oliveira, 2010). 
These more recent drugs show combined DA D2 and 
serotonin 5-HT2 antagonist properties, which suggest 
that the antagonist action in both 5-HT2 and D2 receptor 
are important for the antipsychotic effect of atypical 
agents (Brunton, Chabner, Knowmann, 2012). This 
same group of drugs there also the bexpiprazole and 
cariprazine that present mechanisms of action similar to 
aripiprazole, however differ in pharmacodynamic profile. 
The bexpiprazole has low intrinsic activity at D2 receptor 
and has approximately thenfold higher affinity in receptor 
5-HT1 and 5-HT2, potentially enhancing tolerability 
(Citrome, 2015). Already Cariprazine, when compared 
to aripiprazole, presente similar activity in receptor D2 
and approximately three to thenfold higher affinity in 
receptors D3 then D2, and although both are effective 
in the modulation of psychotics disorders, is not known 
whether there are clinical advantages in drugs that have 
overlapping activity in D3 receptors over D2 (Ceskova, 
Silhan, 2018).
Thereby, aripiprazole is the only drug of this class 
that exhibits partial D2 receptor agonism and 5HT2 
antagonism, which gives it an atypical clinical profile of 
antipsychotic efficacy with limited EPE and less intense 
(Church, Hamer, Ulbrich, 2010). The partial D2 receptor 
agonism may regulate DA levels by by an antagonist 
action in the subcortical and agonist action in the cortical 
region, thus regulating the positive and negative symptoms 
(Smith et al., 2008). 
Clozapine was the first atypical antipsychotic 
developed that showed satisfactory improvements in 
positive and negative symptoms of schizophrenia. In 
addition, it showed additional advantages regarding the 
efficacy in refractory cases and cases of complicated 
treatment. However, it is associated with the occurence of 
agranulocytosis (reduction or absence of leukocytes), so 
that in most cases it is employed when the patient does not 
respond to treatment with other drugs. Patients who use 
clozapine must follow periodic monitoring of leukocyte 
levels in order to minimize the impacts caused by the drug 
(Fleischhacker, Nasrallah, Newcomer et al.; 2005). The 
other SGAs also show satisfactory results in the treatment 
of schizophrenia, but do not induce agranulocytosis, which 
makes them the first choice for the treatment (Golan et al., 
2014).
However, the arrival of new antipsychotics 
brought a series of new adverse effects that show 
significant implications in the health of patients; this 
pharmacological variety of atypical antipsychotics is 
associated not only to the additional therapeutic benefits, 
but also to the interaction of the drug to certain receptors, 
that can increase predisposition of a drug to cause adverse 
effects, being this differential between the adverse effects 
caused by typical and atypical antipsychotics, that is, 
the binding capacity and affinity to a certain receptor, as 
two different antipsychotics may show similar adverse 
effects for certain types of receptors. On the other hand, 
an antipsychotic can be more effective in the reduction 
of symptoms compared to another due to its capacity 
of adequately binding to a certain receptor (Nasrallah, 
2008). Some actions of these drugs in other receptors are 
demonstrated in Table I.
Adverse effects 
Antipsychotics, in general, seem to be associated 
to different degrees of adverse metabolic effects, 
including weight gain and its complications, metabolic 
alterations such as Diabetes Mellitus type 2 (DM2), 
compromised lipid profile, hypertension, dyslipidemia 
and, in some more severe cases, cardiovascular disease 
(Azevedo et al., 2006). Usually, changes in lipid profile 
are shown in the first six months of treatment and the 
drugs that show more propensity to cause these alterations 
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are olanzapine, clozapine and quetiapine, and in a 
lower degree aripiprazole, risperidone and ziprasidone 
(Foley et al., 2014).
The mechanism by which antipsychotics cause 
metabolic disturbances is still unknown, but it is assumed 
that it may be related to the weight gain and peripheric 
insulin resistance, as well as to the worsening of the 
pre-diabetic patients’ glicemic control, who can develop 
DM2 (Kato et al., 2015). However, other hypothesis 
suggest that these alterations independ from weight gain 
or obesity, but that these antipsychotic drugs can interact 
with glucose transportes, altering the plasmatic glucose 
level (Fleischhacker, Nasrallah, Newcomer, 2005).
It is known that the binding of atypical antipsychotics 
to 5HT2, M (muscarinic), and/or H1(histamine) receptors, 
have been associated to metabolic alterations that 
can compromisse the patient’s physical well-being 
(Correia et al., 2008). The drug’s affinity to histamine H1 
and to 5HT2 serotonin receptors is linked to the weight 
gain, while the affinity to muscarinic receptors and its 
blockade is linked to anticholinergic adverse effects, 
such as dry mouth, constipation, blurred vision, increased 
prolactin secretion, among others. A meta-analysis 
indicated that the blockade of H1 receptors may interfere 
with the suppression of appetite mediated by leptin, an 
affect that can lead to weight gain and insulin resistance 
(Smith et al., 2008). Such complications include weight 
gain, propensity to diabetes and cardiovascular disease, 
which are probably linked to the antagonist action of 
certain drugs in these receptors (Rang et al., 2016).
Among the drugs responsible for causing the 
metabolic disturbances, it is estimated that clozapine 
and olanzapine may be related to the greater incidence of 
weight gain in comparison to ziprasidone and aripiprazole, 
which seem to have minimum or no effect (Muench, 
Hamer, 2010). There are several studies correlating such 
weight gain throughout the treatment period with these 
drugs. The average weight gain estimated to longer than 
a year is around 1 kg with aripiprazole and ziprasidone, 
1,5 kg with amisulpride, 2-3 kg with quetiapine and 
risperidone, more than 6 kg with olanzapine and 7,8 kg 
with clozapine, including possible significant individual 
differences in weight gain based to the individual’s 
lifestyle and diet. The risks of weight gain are greater in 
patients with a first episode of psychosis, who have not 
been previously exposed to antipsychotic drugs, compared 
to patients of long-term treatment. Thus, young people that 
present the first psychotic crises and begin treatment with 
these drugs are more likely to show weight gain (Viewag, 
Hasnain, 2012).
Nevertheless, the advances in the treatment for 
schizophrenia are directed to the development of more 
selective agents within the current drug classes, as well 
as a better understanding of pathophysiology, in order to 
offer a more effective and safer treatment for the patient 
(Helbert, 2014). Among them, aripiprazole is one of 
the most recent SGA agent, being associated to a better 
tolerability, adhesion to treatment, less intense EPE and 
low weight gain, which suggests less metabolic alterations 
which affect the patient’s health in comparison to other 
drugs from the same class (Fleischhacker, Nasrallah, 
Newcomer, 2005).
Metabolic syndrome
In addition to the several adverse effects related to 
the use of antipsychotics, the increase of health problems 
of the schizophrenic population is often times associated 
TABLE I - Affinity of antypshychotics drugs on receptors 
Drugs
Affinity of receptors Minimum 
effective dose 
(Mg)D2 5HT2 α1 H1 MAch
Chlorpromazine ++ +++ +++ +++ ++ 100
Haloperidol +++ +++ ++ +++ + 2
Clozapine + +++ +++ ++++ ++ 50
Olanzapine ++ +++ ++ +++ ++ 5
Quetiapine + + +++ +++ + 150
Risperidona +++ +++ +++ ++ - 4
Ziprasidone +++ ++++ +++ ++ - 40
Aripiprazole ++++ +++ ++ ++ - 10
Nasrallah, 2008; Golan, Tashjian Jr, et al., 2014; Helbert, 2014.
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to a group of cardiovascular risk factors usually correlated 
to greater abdominal fat deposition and peripheric 
insulin resistance, wich predisposes the patient not 
only to diabetes, but also to the development of other 
comorbidities, such as, obsesity, arterial hypertension 
(AH) and dyslipidemia, a situation named Metabolic 
Syndrome (MS). The life expectancy of these individuals 
is reduced by about 20% when compared to the general 
population, due to clinical conditions of the disease, 
such as weight gain, diabetes, metabolic syndrome and 
cardiovascular disease (Cordioli et al., 2014). It is worth 
mentioning that the association of MS with cardiovascular 
disease, increases general mortality rates in about 
1,5 times and cardiovascular mortality rates in about 
2,5 times (Brandão et al., 2005).
Studies show that psychiatric patients have a 
greater risk of developing MS. Data from the Clinical 
Antipsychotic Trials of Intervention Effectiveness 
(CATIE) project, indicated that around 40% of these 
individuals develop MS, with a percentual of 51,6% 
of women and 36% of men (McEvoy et al., 2005). 
According to WHO, the evaluation of insulin resistance 
and the disturbance of glucose metabolism are the main 
starting point to evaluate these physiological alterations. 
The National Cholesterol Education Program (NECP) 
described the components of the syndrome in order 
to facilitate its diagnosis, and the work is known as 
ATP III (Adult Treatment Panel). According to the 
NCEP-ATP III, MS represents the combination of at 
least three of the following components: abdominal 
obesity, alteration in the levels of triglycerides and HDL 
lipoproteins, hypertension, increased fasting blood sugar 
and hyperinsulinemia (Brandão et al., 2005). The criteria 
for the diagnosis of MS according to the NCEP-ATP III 
are shown in the Table II.
The factors related to the development of MS in 
schizophrenic patients are partly influenced by aspects of 
the disease, such as the negativ symptoms and vulnerability 
to stress, which reflects in a sedentary lifestyle, lack of 
regular physical activity, bad eating habits, use of doping 
substances and high levels of smoking. On the other hand, 
the antipsychotics used for the treatment of schizophrenia 
have been largely correlated to the manifestation of these 
alterations due to the propensity of inducing weight gain 
(Hert et al., 2009).
Obesity and specifically abdominal obesity 
associated to insulin resistance is considered to be the 
fator by which the excessive weight leads to glycemic 
metabolic dysfunctions. This insulin resistance promotes 
greater liberation of free fatty acids in the bloodstream, 
mainly by the abdominal adipose tissue, consequently, 
less insulin is reuptaken, leading to the development 
of hyperglycemia and greater risk of develping DM2 
(Teixeira, Rocha, 2006). 
In some case-control studies, it was shown that 
hyperglycemia tends to occurs around six weeks after the 
beginning of the treatment with SGA; some cases were 
reversed with the interruption of the treatment, which 
suggests a direct correlation between the drugs in insulin 
resistance (Church, Hamer, Ulbrich, 2010). It is also 
possible tthat the blockade of 5HT1 receptors of the β 
pancreatic cells and the inhibition of insulin secretion by 
α adrenergic receptors may be pointed as possible causes 
for DM2 (Pramyothin, Khaodhiar, 2010).
It has been noted an increase in plasmatic levels of 
leptin in patients after treatment with typical and atypical 
antipsychotic agentes. Leptin is a proteic hormone 
produced by adipose cells that acts on the hypothalamus 
regulating food intake and energetic metabolism 
(Wirshing, 2004). There is evidence that obese patients 
are resistant to this effect of leptin, but there is no 
significant evidence that suggests that these drugs have 
a direct relation with this resistance, nor that they have 
a primary effect over the function of β pancreatic cells 
(Peet, 2004).
Besides ,  there  is  corre la t ion between the 
administration of antipsychotic drugs and the induction 
of dyslipidemias; this mechanism has not yet been 
completely elucidated, although it is supposed that 
insulin resistance might be the central factor for this 
mechanism, as there is alteration of the plasmatic lipid 
concentration, including reduced serum HDL (high 
TABLE II - Components of metabolic syndrome according to 
NCEP-ATP III
 
Components Levels
Abdominal obesity through 
abdominal circumference
Men > 102 cm 
Women > 88 cm
Triglycerides ≥ 150 mg/dL 
HDL cholesterol
Men < 40 mg/dL
Women < 50 mg/dL
Blood pressure ≥ 130 mmHg ou ≥ 85 mmHg 
Fasting blood glucose ≥ 110 mg/dL
I Brazilian Guideline for Diagnosis and Treatment of Metabolic 
Syndrome, 2005
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density, cholesterol carrier) lipoprotein levels and higher 
VLDL (very low density, triglyceride carrier) lipoprotein 
levels (Vieweg, Hasnain, 2012). This increased cholesterol 
and triglyceride levels is associated to the development 
of cardiovascular diseases or their worsening, such as 
ischemia or myocardial infarction; as well as of alterations 
in laboratory results, such as echocardiogram (ECG), the 
antipsychotics tend to increase the QT interval (interval 
of ventricular depolarization and repolarization) which 
implicates in the development of the torsade points, a 
type of ventricular arrhythmia that can lead to syncope 
and progress to ventricular fibrilation and sudden death 
(Marder et al., 2004).
Correl and cols (2009) performed a short-lasting 
non-randomized study regarding weight gain and 
metabolic alterations for a period of 12 weeks in children 
and adolescents of ages between 4-19 years old that 
were diagnosed with humor disorders, schizophrenia or 
agressive behavior, and that had not yet been treated. 
Prescriptions were made before the patients joined the 
study, using SGAs, including olanzapine, risperidone, 
quetiapine and aripiprazole; in order to compare the 
effects of a drug with the effect of another, doctors were 
authorized to change the dosage and prescribe other drugs 
along the study. There were 338 patients that applied for 
the study, and 272 returned for the follow-up, as 15 of 
these patients refused to follow the treatment of became 
incompatible, being placed in the control group. At the 
end of the first three months of treatment, all drugs had 
caused fast weight gain, with na increase of 4,4 kg with 
aripiprazol, 5,3 kg with risperidone, 6,0 kg with quetipaine 
and 8,5 kg with olanzapine, compared to 0,2 kg of the 
control group.
These results suggest that the weight gain associated 
to antipsychotic therapy is more pronounced in children 
and adolescents than in adults. Infant psychiatrists have 
clinically observed significant weight gain in children 
during antipsychotic treatment and this is particularly 
worrisome, due to the long-term effect of excessive weight 
and obesity in the patient’s health and the prevalence of 
excessive weight seen in children and adolescents in the 
general population (Fleischhacker, Nasrallah, Newcomer, 
2005).
However, it is extremely important to have health 
vigilance as a way to promote specific healthcare to 
these patients, in order to minimize the impacts caused 
by schizophrenia per se and by the other adverse 
effects caused partly by the drugs, showing patients the 
importance of treatment adhesion and measuring the risks 
and benefits that the drugs offer, always prioritizing more 
safety and efficacy.
Aripiprazole
Throughout time, it has been noted the need to 
study and develop new drugs for the treatment of mental 
disorders such as schizophrenia, in order to search for 
new mechanisms that are more effective, safe and that 
show better results in therapy. Among these drugs there 
is aripiprazole, a second generation antipsychotic that 
has shown significant better results in the treatment 
of several mental disorders, such as bipolar disorder, 
refractory depression and schizophrenia (Sarin, Del Porto, 
2009). These indications have been proposed in 2002 
by the Food and Drug Administration (FDA), who has 
approved the indication of aripiprazole for the treatment of 
schizophrenia in adults and adolescents, for the treatment 
of bipolar disorder with manic episodes, and recently has 
also been approved for the treatment of irritability and 
autism in children and adolescents (Belloso, Loza, 2011).
Aripiprazole has been associated to a significant 
reduction of the positive and negative symptoms of 
schizophrenia, and this effectiveness is explained by 
its different mechanism of action that involves partial 
agonism/antagonism in different brain regions, where 
there is dopaminergic hypo- or hyperactivity and the 
antagonism of 5HT2 serotonergic receptors (Grunder, 
Kungel, 2006). According to this point of view, in cases 
were there are high levels of dopamine (such as in the 
mesolimbic pathway, involved in the positive symptoms), 
aripiprazole acts as a partial antagonist, reducing 
dopaminergic activity in this region, while in areas with 
low dopamine levels (such as the pre-frontal cortex, which 
is involved in the negative symptoms), the drug binds to 
the dopaminergic receptors and acts as a partial agonist 
resulting in an increase of D2 function (Mailman, Murthy, 
2010); besides, it promotes 5HT2A receptor antagonismo 
modulating serotonin levels. Because it shows different 
pharmacodynamics, it has been mentioned in some studies 
as the first third generation antipsychotic (TGA), which 
is defined as drugs that modulate the complex dopamine-
serotonin (Londero, Massuda, Gama, 2015).
Due to this therapeutic advance, aripiprazole has 
shown better tolerability and consequent less aggressive 
adverse effects in comparison to other antipsychotics; 
Keck Jr and cols (2003) performed a meta-analysis 
regarding safety and tolerability of aripiprazole in the 
acute treatment of schizoaffective disorder, whose more 
common adverse effects reported to aripiprazole were 
headache, insomnia and vomiting.
In addition to the low incidence of adverse effects, 
aripiprazole also shows less metabolic alterations, in 
comparison to other antipsychotics; although published 
D. G. C. Silva, L. K. S. Kanazawa, D. D. Vecchia
Braz. J. Pharm. Sci. 2019;55:e17840Page 8 / 10
data regarding these alterations is limited, the available 
information suggest that treatment with aripiprazole is 
not much assoaciated with the risk of developing diabetes 
of dyslipdemia or with the incidence of alterations in 
glucose and lipid levels that can affect the patient’s health 
(Fleischhacker, Nasrallah, Newcomer, 2005). In a short-
term comparative study, the inicidence of hyperglicemia 
caused by aripiprazole was evaluated in comparison to 
placebo; the results showed that the use of aripiprazole 
was well-tolerated, and has reversed the hyperglycemia 
caused by other antipsychotics (Bowles, Levin, 2003).
Furthermore, the use of aripiprazole is associated 
with minimal body weight alterations, with an average 
increase of 0,7 kg in a short period of 4 to 6 weeks, and 
around 1,05 kg in a long-term treatment (Melnik et al., 
2010). When compared to typical antipsychotics, 
aripiprazole shows less risk of promoting akathisia 
(subjective feeling of internal restlessness), less occurence 
of orthostatic hypotension, low variations in plasmatic 
prolactin levels, and little significant alterations in the 
prolongation of the QT interval of the ecocardiogram 
(Keltner, Johnson, 2002).
Thus, one can notice that these significant clinical 
complications such as MS and diabetes can be prevented 
or even reversed employing an antipsychotic with good 
clinical safety profile, such as aripiprazole. Besides, it 
can be hypothesized that aripiprazole, with its superior 
metabolic profile, can be used as a more rentable first line 
option to improve or even normalize the metabolic state 
of patients that develop these disturbances, and can also 
be employed in cases of treatment resistance (Hert et al., 
2007).
RESULTS AND DISCUSSION
It is known that the wide range of drugs available for 
the treatment of mental disorders are clinically effective 
for the treatment of diseases such as schizophrenia, 
showing significant clinical improvement of symptoms 
and quality of life for the patients, which sometimes can 
be the main factors that separate these individuals from 
healthy individuals.
Many antipsychotic drugs are intimately associated 
to the occurance of a series of adverse effects that are 
directly related to their pharmacological profile. However, 
in cases where the schizophrenic patient is predisposed 
to develop a primary pathologic condition, such as DM2, 
obesity, dyslipidemia, hypertension or any other, there 
must be an evaluation of the cost-benefit of the treatment, 
taking into account that these drugs can help to develop or 
attenuate the existing cases. However, the development of 
new drugs, that have different mechanisms of action, has 
been cardinal for minimizing these metabolic disturbances, 
as they may offer better clinical and therapeutic results and 
safety for the patient.
Thus, exceptionally, aripiprazole has been shown 
positively superior from other drugs used for the treament 
of schizophrenia, showing satisfactory clinical profile with 
good tolerability and lower incidence of adverse effects, 
and can be employed for the correction of adverse effects 
caused by the other drugs, such as metabolic syndrome, 
or in refractory cases.
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